Cargando…

Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?

Direct oral anticoagulants (DOAC) are now recommended for the treatment of cancer-associated thrombosis (CAT) based on the results of dedicated trials demonstrating that DOAC are non-inferior to low molecular weight heparins in preventing recurrent venous thromboembolism (VTE) in this population. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frere, Corinne, Crichi, Benjamin, Lejeune, Manon, Spano, Jean-Philippe, Janus, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226070/ https://www.ncbi.nlm.nih.gov/pubmed/32283621 http://dx.doi.org/10.3390/cancers12040917

Ejemplares similares

Hemostasis testing in patients with liver dysfunction: Advantages and caveats
por: Nguyen, Guillaume, et al.
Publicado: (2021)

Menstruation, anticoagulation, and contraception: VTE and uterine bleeding
por: Samuelson Bannow, Bethany, et al.
Publicado: (2021)

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
por: Khorana, Alok A., et al.
Publicado: (2018)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Duration of anticoagulant therapy and VTE recurrence in patients with cancer
por: Khorana, Alok A., et al.
Publicado: (2019)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Extended anticoagulation for VTE: what evidence justifies it?
por: Walia, Anushka, et al.
Publicado: (2023)

Spontaneous rectal sheath bleed while on DOAC anticoagulation
por: de Courcy, Louis, et al.
Publicado: (2023)

Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies
por: Frere, Corinne, et al.
Publicado: (2019)

Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE)
por: Tiperneni, Raghu, et al.
Publicado: (2022)

Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry)
por: Ikeda, Masataka, et al.
Publicado: (2022)

One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis)
por: Awano, Nobuyasu, et al.
Publicado: (2022)

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism
por: Klok, Frederikus A., et al.
Publicado: (2019)

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
por: Burnett, Allison E., et al.
Publicado: (2016)

Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Frere, Corinne, et al.
Publicado: (2020)

Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study
por: Klok, Frederikus A., et al.
Publicado: (2018)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges
por: Farge, Dominique, et al.
Publicado: (2019)

Comparison of VTE risk scores in guidelines for VTE diagnosis in nonsurgical hospitalized patients with suspected VTE
por: Xiong, Wei, et al.
Publicado: (2023)

Cardiovascular outcomes in hospitalized patients with COVID-19 and history of cancer: a CORONA-VTE analysis
por: Khairani, C D, et al.
Publicado: (2021)

Intraprostatic injection of tranexamic acid to control refractory bleeding while maintaining therapeutic anticoagulation
por: Le, Brian, et al.
Publicado: (2019)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

How to Build the Plane While Flying: VTE/PE Thromboprophylaxis Clinical Guidelines for COVID-19 Patients
por: Costa, Alessandro, et al.
Publicado: (2020)

Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer
por: Glassman, Deanna, et al.
Publicado: (2022)

A Retrospective Review of Upper Gastrointestinal Bleed Outcomes During Hospital Admission While on Oral Anticoagulation
por: Scibelli, Nicolina, et al.
Publicado: (2021)

Trial Protocol: A randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study)
por: Tullett, Jayne, et al.
Publicado: (2013)

"Cancer Survivorship", kutane Toxizitäten und VTE heiß diskutiert
por: Ortner, Petra
Publicado: (2021)

Risk Assessment for Cancer-Associated VTE: Diversifying the Evidence Base
por: Khorana, Alok A.
Publicado: (2021)

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE
por: Schapkaitz, E., et al.
Publicado: (2023)

Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre
por: Pelletier, Ryan
Publicado: (2021)

VTE risk assessment in pregnancy
por: Ewins, Karl, et al.
Publicado: (2019)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
por: Amin, A., et al.
Publicado: (2009)

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2016)

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis
por: Jiménez, David, et al.
Publicado: (2021)

Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya
por: Njuguna, Dennis, et al.
Publicado: (2023)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models
por: Riondino, Silvia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ae1qou0v03qja3ipe5t29posm6